Biosimilars Market to 2023 – Growing Steady at 31.7% CAGR and Projected to Reach US$ 23.63 Billion

Biosimilars Market report analyzed by supply demand with global trends analysis and this report shows the current market status with industry chain structure of Biosimilars industry.

Pune, India - April 8, 2019 /MarketersMedia/ —

The “Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023” report presents an in-depth assessment of the Biosimilars including enabling technologies, key trends, market drivers, challenges, deployment case studies, standardization, opportunities, future roadmap, value chain, Top key player profiles and strategies. The report also presents market size forecasts from 2018 till 2023.

Get Here Free Sample Research Report of “Biosimilars Market” at https://www.reportsnreports.com/contacts/requestsample.aspx?name=270786

The Biosimilars Market is expected to reach US$ 23.63 Billion by 2023 from US$ 5.95 Billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness, rising incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.

“The recombinant glycosylated protein segment is anticipated to grow at the fastest growth rate during the forecast period.”
The Biosimilars market by product is categorized into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant glycosylated proteins segment is expected to register the highest CAGR during the forecast period. The factors driving the market for glycosylated proteins are the broad therapeutic area of these proteins; presence of biosimilar versions of monoclonal antibodies at lower prices compared to reference products; numerous biologic drugs underclass monoclonal antibody, follitropin, and erythropoietin going off-patent; and numerous products in the pipeline.

By type of manufacturing, the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The contract manufacturing segment is expected to grow at the highest CAGR during the forecast period. CMOs provide cost-saving benefits to companies in terms of facilities, equipment, and labor costs.

“Asia is estimated to register the highest CAGR during the study period.”
On the basis of region, the biosimilars market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Many Asian countries such as India, China, South Korea, and Japan have emerged as potential markets for biosimilars. Many emerging economies in the region are also establishing biosimilar pathways. Moreover, leading market players are outsourcing manufacturing and R&D activities to countries in the Asia Pacific region due to the availability of highly skilled resources at lower costs.

Browse 176 Tables, 37 Figures, 10 Companies, spread across 181 pages available at https://www.reportsnreports.com/purchase.aspx?name=270786

Report Highlights:
• To profile key players and comprehensively analyze their market shares and core competencies in terms of market developments and growth strategies
• To forecast the size of the market with respect to four main regional segments, namely, North America, Europe, Asia, and the Rest of the World (RoW)
• To define, describe, segment, and forecast the biosimilars market by product, type of manufacturing, disease, and region
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To track and analyze competitive developments such as collaborations, regulatory approvals, partnerships, acquisitions, and product launches in the biosimilars market

Target Audience for Biosimilars Market: Private equity companies and venture capital firms, Biopharmaceutical drug manufacturers (biosimilars and biologics), Healthcare service providers (hospitals and independent physicians), Health insurance payers, Research and consulting service firms, Contract research organizations (CROs), Pharmaceutical and medical associations, Contract manufacturing organizations (CMOs).

Ask Discount @ https://www.reportsnreports.com/contacts/discount.aspx?name=270786

Top Companies in the Biosimilars Market inclure are Pfizer (US), Sandoz (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea).

Competitive Landscape of Biosimilars Market
1 Overview
2 Market Share Analysis, 2016
3 Competitive Scenario
3.1 Product Launches and Product Approvals
3.2 Partnerships, Collaborations, and Agreements
3.3 Acquisitions
3.4 Expansions

Contact Info:
Name: Snehal Shete
Email: Send Email
Organization: Reportsandreports
Address: Tower B5, Office 101, Magarpatta City SEZ, Pune-411013, India
Phone: +1 888 391 5441
Website: https://www.reportsnreports.com/reports/270786-biosimilars-market-product-recombinant-non-glycosylated-proteins-insulin-filgrastim-somatropin-glycosylated-monoclonal-antibodies-erythropoietin-peptides-glucagon-calcitonin-application-oncology-blood-disorders-global-forecast-to-2018.html

Source URL: https://marketersmedia.com/biosimilars-market-to-2023-growing-steady-at-317-cagr-and-projected-to-reach-us-2363-billion/499943

Source: MarketersMedia

Release ID: 499943